CU20160044A7 - DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA - Google Patents

DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA

Info

Publication number
CU20160044A7
CU20160044A7 CUP2016000044A CU20160044A CU20160044A7 CU 20160044 A7 CU20160044 A7 CU 20160044A7 CU P2016000044 A CUP2016000044 A CU P2016000044A CU 20160044 A CU20160044 A CU 20160044A CU 20160044 A7 CU20160044 A7 CU 20160044A7
Authority
CU
Cuba
Prior art keywords
antagonists
tetrahydrotiene
dioxo
adenosine
pyrimidine
Prior art date
Application number
CUP2016000044A
Other languages
English (en)
Inventor
Michael Härter
Martina Delbeck
Bernd Kalthof
Klemens Lustig
Niels Lindner
Raimund Kast
Pierre Wasnaire
Frank Süssmeier
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20160044A7 publication Critical patent/CU20160044A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente soiLicitud se relaciona con novedosos derivados de 2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidina-6-carboxamida ("tienouracil"-carboxamidas), con fórmula general I ESPACIO PARA FÓRMULA como antagonistas de receptores A2b de adenosina y a los medicamentos que los comprenden, solos o en combinación con uno o más compuestos activos adicionales seleccionados del grupo de los inhibidores de PDE 5 activadores de sGC, estimuladores de sGC, análogos de protaciclina, antagonistas de protaciclina, antagonistas de endotelina, de los agentes antifibróticos, los agentes antiinflamatorios, inmunomodulantes inmunosupresores y/o citotóxivos y/o los compuestos de inhibición de la cascada de transducción de la señal
CUP2016000044A 2013-10-07 2016-04-07 DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA CU20160044A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13187487 2013-10-07
EP14152518 2014-01-24
PCT/EP2014/071113 WO2015052065A1 (de) 2013-10-07 2014-10-02 Cyclische thienouracil-carboxamide und ihre verwendung

Publications (1)

Publication Number Publication Date
CU20160044A7 true CU20160044A7 (es) 2016-09-30

Family

ID=51655757

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000044A CU20160044A7 (es) 2013-10-07 2016-04-07 DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA

Country Status (24)

Country Link
US (2) US9604996B2 (es)
EP (1) EP3055313B1 (es)
JP (1) JP2016532721A (es)
KR (1) KR20160065957A (es)
CN (1) CN105793267B (es)
AP (1) AP2016009128A0 (es)
AU (1) AU2014334040A1 (es)
BR (1) BR112016007238A2 (es)
CA (1) CA2926223A1 (es)
CR (1) CR20160155A (es)
CU (1) CU20160044A7 (es)
DO (1) DOP2016000076A (es)
EA (1) EA201600318A1 (es)
ES (1) ES2659043T3 (es)
IL (1) IL244751A0 (es)
MX (1) MX2016004250A (es)
NI (1) NI201600047A (es)
PE (1) PE20160562A1 (es)
PH (1) PH12016500608A1 (es)
SG (1) SG11201602397XA (es)
TN (1) TN2016000121A1 (es)
TW (1) TW201607950A (es)
UY (1) UY35771A (es)
WO (1) WO2015052065A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032137B1 (ru) * 2014-11-03 2019-04-30 Байер Фарма Акциенгезельшафт Производные гидроксиалкил-замещенного фенилтриазола и их применение
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
CA3030021A1 (en) * 2016-07-07 2018-01-11 Cardurion Pharmaceuticals, Llc Methods for treatment of heart failure
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
SG11201902588PA (en) * 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
MA71568A (fr) * 2022-08-16 2025-05-30 Cms Research & Development Pte. Ltd. Forme saline et forme cristalline de dérivé de thiénopyrimidinone

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
PT1107973E (pt) * 1998-08-28 2004-03-31 Astrazeneca Ab Novas tieno¬2,3-d| pirimidinodionas processo para a sua preparacao e sua utilizacao em terapia
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
BR0207216A (pt) * 2001-02-14 2004-03-09 Warner Lambert Co Derivados de tieno 2,3-d-pirimidindiona como inibidores de metaloproteinase matriz
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
AU2002366801B8 (en) * 2001-12-20 2009-05-21 Osi Pharmaceuticals, Inc. Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1847541A4 (en) 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
MX2008014690A (es) 2006-05-18 2008-11-27 Hoffmann La Roche Derivados de tiazolo-pirimidina/piridina-urea.
US7776868B2 (en) * 2006-12-01 2010-08-17 Gilead Palo Alto, Inc. Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
WO2008115912A1 (en) 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US7947629B2 (en) * 2007-08-06 2011-05-24 Schlumberger Technology Corporation Method of acidizing sandstone formations
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
PT2394999E (pt) 2009-02-06 2014-05-02 Nippon Shinyaku Co Ltd Derivado de aminopirazina e medicamento correspondente
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP3628320B1 (en) 2011-11-11 2022-03-16 Gilead Apollo, LLC Acc inhibitors and uses thereof

Also Published As

Publication number Publication date
PE20160562A1 (es) 2016-06-05
DOP2016000076A (es) 2016-05-15
KR20160065957A (ko) 2016-06-09
EP3055313B1 (de) 2017-11-22
EP3055313A1 (de) 2016-08-17
SG11201602397XA (en) 2016-05-30
US9604996B2 (en) 2017-03-28
CN105793267B (zh) 2018-02-06
TW201607950A (zh) 2016-03-01
BR112016007238A2 (pt) 2017-08-01
TN2016000121A1 (en) 2017-10-06
ES2659043T3 (es) 2018-03-13
CN105793267A (zh) 2016-07-20
CR20160155A (es) 2016-07-21
NI201600047A (es) 2016-09-21
JP2016532721A (ja) 2016-10-20
IL244751A0 (en) 2016-04-21
PH12016500608A1 (en) 2016-06-13
AP2016009128A0 (en) 2016-04-30
EA201600318A1 (ru) 2016-09-30
CA2926223A1 (en) 2015-04-16
WO2015052065A1 (de) 2015-04-16
MX2016004250A (es) 2016-07-12
AU2014334040A1 (en) 2016-04-28
US20160244461A1 (en) 2016-08-25
US20170145029A1 (en) 2017-05-25
UY35771A (es) 2015-04-30

Similar Documents

Publication Publication Date Title
CU20160044A7 (es) DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA
GT201400196A (es) Compuestos de heterociclilo
SV2016005234A (es) Análogos de cortistatina y síntesis y usos de los mismos
NI201300103A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [ 2, 3-d] PIRIMIDINA TROPOMIOSINA
CU24363B1 (es) Compuestos peptidomiméticos cíclicos
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2015000206A (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas janus (jak)
PE20191710A1 (es) Modulador del receptor de androgeno y usos de este
PH12014502540A1 (en) Benzimidazole-proline derivatives
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
GT201300291A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias.
CU20170123A7 (es) Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b
CR20180323A (es) Derivados de indol n-sustituídos como moduladores de los receptores de pge2
DOP2016000011A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO
PH12016500885A1 (en) Novel heterocyclic compounds
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MX2015014081A (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
EA033106B1 (ru) Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения
BR112016001106A8 (pt) Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx
UA112586C2 (uk) Похідні бензімідазолпроліну